Can SGLT-2 inhibitors resolve the heart failure burden of diabetes mellitus - Is it empaglifozin or the class?

被引：0
|
作者：
Tschoepe, Diethelm [1 ]
机构：
[1] Ruhr Univ Bochum, Heart & Diabet Ctr North Rhine Westphalia Bad Oey, Diabet Ctr, Bochum, Germany
来源：
JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2017年 / 31卷 / 07期
关键词：
EMPAGLIFLOZIN; MORTALITY; OUTCOMES; TYPE-1;
D O I：
10.1016/j.jdiacomp.2017.04.020
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1075 / 1076
页数：2
相关论文
共 50 条
  • [31] SGLT-2 inhibitors in heart failure and chronic kidney disease: A review for internists
    Jaswaney, Rahul
    Sokoloff, Samantha
    Rakita, Val
    Rubin, Daniel J.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (07) : 415 - 423
  • [32] SGLT-2 Inhibitors for Cardiovascular Outcomes in Heart Failure With Preserved Ejection Fraction
    Carek, Stephen
    Yurgil, Jacqueline
    Mounsey, Anne
    AMERICAN FAMILY PHYSICIAN, 2023, 107 (01) : 81 - 82
  • [33] Double Edged Sword: SGLT-2 Inhibitors in the Immunosuppressed Heart Failure Patient
    Brown, Christina
    Addis, Jessica
    Mohamed, Fazad
    CIRCULATION, 2023, 148
  • [34] Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies
    Sheng Fu
    Sheldon E. Litwin
    Ryan J. Tedford
    Nature Medicine, 2021, 27 : 1872 - 1873
  • [35] SGLT-2 inhibitors in heart failure: Time for broader eligibility and earlier initiation
    Ferro, Enrico G.
    Pitt, Bertram
    Bhatt, Deepak L.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2021, 88 (11) : 601 - 606
  • [36] EMPULSE trial: Time to use SGLT-2 inhibitors in acute heart failure?
    Roy, Shubhajeet
    Saxena, Mehul
    Pradhan, Akshyaya
    NATIONAL MEDICAL JOURNAL OF INDIA, 2024, 37 (02): : 93 - 94
  • [37] CARDIOVASCULAR DISEASE SGLT-2 inhibitors in heart failure: a new therapeutic avenue
    Vaduganathan, Muthiah
    Butler, Javed
    NATURE MEDICINE, 2019, 25 (11) : 1653 - 1654
  • [38] Lessons from SGLT-2 inhibitors: rethinking endpoints for heart failure studies
    Fu, Sheng
    Litwin, Sheldon E.
    Tedford, Ryan J.
    NATURE MEDICINE, 2021, 27 (11) : 1872 - 1873
  • [39] SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature
    Imprialos, Konstantinos
    Faselis, Charles
    Boutari, Chrysoula
    Stavropoulos, Konstantinos
    Athyros, Vasilios
    Karagiannis, Asterios
    Doumas, Michael
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (10) : 1510 - 1521
  • [40] Diabetes Mellitus and Heart Failure: Epidemiology, Pathophysiologic Mechanisms, and the Role of SGLT2 Inhibitors
    Theofilis, Panagiotis
    Oikonomou, Evangelos
    Tsioufis, Konstantinos
    Tousoulis, Dimitris
    LIFE-BASEL, 2023, 13 (02):
12345